Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.

Summary: For patients fighting advanced colon cancer, the drug Bevacizumab offers a powerful shield, but it comes with a double-edged sword. A comprehensive review of over 3,000 patients confirms that this medication significantly extends life and stops tumors from growing for longer periods. However, it also raises the chances of specific side effects, most notably high blood pressure, bleeding, and rare but serious holes in the digestive tract. Despite these dangers, the data shows that for most patients, the life-extending benefits are substantial enough to make the risks worth taking.